… , erlotinib patients were included without knowledge of the EGFR mutation status in tumour
tissue. As erlotinib is now increasingly used in pre-selected patients, the duration of use may …

… insight into patients' experiences with the use of erlotinib in … important role in the way patients
use erlotinib. We expect that … develop interventions to support patients. This approach will …

… of never smokers (TRIBUTE = 72 patients; TALENT = 10 patients) receiving erlotinib contributed
to researchers being more selective in their choice of patients for EGFR TKIs. The lack of …

… A retrospective data review was conducted at our institute to study patients who were treated
with erlotinib for metastatic NSCLC between December 1, 2004, and December 31, 2006. …

… patient experience during treatment is important to both regulatory authorities and to patients
… We identified the symptoms and side effects experienced by patients with advanced non-…

… However, the monthly treatment cost for erlotinib is high, raising … on the use of erlotinib in
advanced non-small-cell lung cancer. … We use cookies to improve your website experience. To …

… and patient perceptions of patients’ medication experiences. The … experience of taking oral
targeted therapy in patients with … and patients’ experiences with the use of erlotinib in non-…

… recommended daily dose of erlotinib for patients with NSCLC was, therefore, determined to
be 150 mg/day Citation[11,14]. Importantly, if patients experience intolerable side effects that …

… by health plans based on their experiences with erlotinib. In addition, a … use of erlotinib
as first-line therapy. Other cost–utility models explored the cost–utility of erlotinib in patient …

… of patients and investigators, the extent to which patients and … patients in the erlotinib arm
were significantly more likely to develop a rash and experience diarrhoea than patients in the …